Tech Company Financing Transactions
Edesa Biotech Funding Round
Private investors participated in a $16.8 million capital raise for Edesa Biotech. The round was announced by the company on 10/12/2023.
Transaction Overview
Company Name
Announced On
10/12/2023
Transaction Type
Debt
Amount
$16,830,000
Round
Undisclosed
Investors
private investors (Par Nijhawan)
Proceeds Purpose
Edesa's current project builds on the success of a government-supported Phase 2 clinical study completed during the pandemic which demonstrated that paridiprubart reduced mortality by 84% among critically ill patients with a severe form of respiratory disease called Acute Respiratory Distress Syndrome (ARDS).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Spy Court
Markham, Ontario, L3R 5H6
CA
Markham, Ontario, L3R 5H6
CA
Phone
Website
Email Address
Overview
Edesa Biotech is a clinical-stage biopharmaceutical company founded by experts in the fields of inflammation, infectious disease and gastroenterology. We are exploring new ways to treat these diseases, including alternatives to topical steroids, which can have serious side-effects. This innovative approach is made possible by proprietary technologies developed to inhibit the inflammatory process or modulate the body's immune response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Par Nijhawan
Browse more venture capital transactions:
Prev: 10/12/2023: Scope3 venture capital transaction
Next: 10/12/2023: Intento venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs